BrainStorm Provides Update on Clinical Trial and Scientific Conference Activities

BrainStorm Provides Update on Clinical Trial and Scientific Conference 
NEW YORK, NY and PETACH TIKVAH, ISRAEL -- (Marketwired) -- 05/21/13
--  BrainStorm Cell Therapeutics (OTCQB: BCLI), a leading developer
of adult stem cell technologies for neurodegenerative diseases, today
provided an update on the company's current and upcoming clinical
trial and scientific conference activities. 
Clinical Trial Activities 
Brainstorm recently performed the 5th transplantation in its ongoing
Phase IIa clinical trial with NurOwn(TM) at the Hadassah Medical
Center in Jerusalem. In this Phase IIa trial, 12 ALS patients are
receiving combined intramuscular and intrathecal administration of
NurOwn cells, in three cohorts, with increasing doses. The study
participants will be monitored for six months following
transplantation. In a recent radio interview on Israel's "Galei
Tzahal," Professor Dimitrios Karussis, Principal Investigator,
discussed the current trial as well as the results of the recently
completed Phase I/II trial, which he referred to as "very
encouraging." A recording of the interview and English translation
can be accessed on BrainStorm's website at: 
In addition, preparation of the Company's IND submission for the
upcoming Phase II trial in the US remains on schedule. BrainStorm
anticipates patient enrollment to begin later this year. 
Upcoming Scientific Conferences 
Professor Dimitrios Karussis, Principal Investigator of BrainStorm's
clinical trials at Jerusalem's Hadassah Medical Center, will make an
oral presentation at Twenty-third Meeting of the European
Neurological Society (ENS) to be held June 8-11 in Barcelona, Spain.
The presentation is scheduled for the Motor Neuron Disease session on
Sunday, June 9th at 16:00. 
Dr. Adrian Harel, BrainStorm's Director of R&D, will be presenting at
the IATI Biomed Israel 2013 Conference to be held June 10-12 in Tel
Aviv. The presentation will be given on Tuesday, June 11th at 14:50.  
Professor Daniel Offen, BrainStorm's Chief Scientific Advisor, will
deliver a poster presentation at the 11th Annual Meeting of the
International Society for Stem Cell Research (ISSCR), to be held June
12-15 in Boston, MA. Prof. Offen will present in Poster Session I on
Wednesday, June 12
th at 6:30 pm. 
About BrainStorm Cell Therapeutics, Inc.
 BrainStorm Cell
Therapeutics Inc. is a biotechnology company engaged in the
development of first-of-its-kind adult stem cell therapies derived
from autologous bone marrow cells for the treatment of
neurodegenerative diseases. The Company holds the rights to develop
and commercialize its NurOwn technology through an exclusive,
worldwide licensing agreement with Ramot, the technology transfer
company of Tel Aviv University. For more information, visit the
company's website at 
Safe Harbor Statement - Statements in this announcement other than
historical data and information constitute "forward-looking
statements" and involve risks and uncertainties that could cause
BrainStorm Cell Therapeutics Inc.'s actual results to differ
materially from those stated or implied by such forward-looking
statements. Terms and phrases such as "may", "should", "would",
"could", "will", "expect", "likely", "believe", "plan", "estimate",
"predict", "potential", and similar terms and phrases are intended to
identify these forward-looking statements. The potential risks and
uncertainties include, without limitation, risks associated with
BrainStorm's limited operating history, history of losses; minimal
working capital, dependence on its license to Ramot's technology;
ability to adequately protect the technology; dependence on key
executives and on its scientific consultants; ability to obtain
required regulatory approvals; and other factors detailed in
BrainStorm's annual report on Form 10-K and quarterly reports on Form
10-Q available at These factors should be
considered carefully, and readers should not place undue reliance on
BrainStorm's forward-looking statements. The forward-looking
statements contained in this press release are based on the beliefs,
expectations and opinions of management as of the date of this press
release. We do not assume any obligation to update forward-looking
statements to reflect actual results or assumptions if circumstances
or management's beliefs, expectations or opinions should change,
unless otherwise required by law. Although we believe that the
expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee future results, levels of activity,
performance or achievements. 
BrainStorm Cell Therapeutics Inc. 
Mr. Alon Natanson
Phone: +972-3-9236384  
LifeSci Advisors, LLC
Michael Rice
Founding Partner
Phone: 646-597-6979 
Press spacebar to pause and continue. Press esc to stop.